Small molecule drugs are defined as chemically synthetic or naturally-derived drugs with low molecular weight. From analgesics to anti-infectives and to cardiovascular, central nervous system, and oncology medicines, small molecules have proven successful for a broad range of indications. For the development of novel small molecules, careful consideration is required to select the appropriate drug development path towards the clinic. Our in-house experts and Program Managers, in conjunction with our vast network of regulatory and subject matter experts, can help you tailor the right program with the clinical end in mind.
I have had the pleasure of working with KreaMedica on several programs. They proactively identified and addressed issues and provided regular updates to ensure everyone was on the same page. Their attention to detail and willingness to take ownership of the project’s success makes them invaluable partners. They are great to work with, and I would highly recommend them to anyone looking for a drug development partner.
They supplemented and filled in gaps in our internal network and worked well with our advisors. They truly wanted to contribute to and be part of the project’s success. I highly recommend Claude, Poulomee, and Rudi as reliable partners for planning and executing toxicological and bioanalytical projects.
I have worked with KreaMedica for many years, and I must credit them for the team’s talent, professionalism, and chemistry. That doesn’t happen by accident. As a consultant, I rely on them as the first line to monitor studies and provide proactive solutions when required.